Table 5—

Association of matrix metalloproteinase(MMP) single nucleotide polymorphisms and the response after the second cycle of chemotherapy for nonsmall cell lung cancer patients

PolymorphismGenotypesStage IIIAStage IIIB+IVStage IIIBStage IV
Patients nResponsePatients nResponsePatients nResponsePatients nResponse
MMP1
 G-1607GGG/G21 (ref)521 (ref)171 (ref)351 (ref)
G/GG+140.8 (0.0–14.6)1180.9 (0.5–1.8)400.9 (0.3–3.2)780.9 (0.4–2.1)
GG/GG
MMP2
 C-735TCC131 (ref)1341 (ref)421 (ref)921 (ref)
CT+TT30.3 (0.0–4.4)361.2 (0.6–2.5)153.2 (0.9–11.5)210.9 (0.3–2.2)
MMP3
 6A-1171 5A6A 6A51 (ref)381 (ref)151 (ref)231 (ref)
6A 5A + 5A 5A111.3 (0.1–10.7)1221.3 (0.6–2.6)427.8 (1.4–147.8)#900.6 (0.2–1.6)
MMP7
 C-153TCC121 (ref)1401 (ref)441 (ref)961 (ref)
CT+TT46.0 (0.5–77.8)291.3 (0.6–2.9)131.9 (0.5–6.9)161.4 (0.5–4.3)
 A-181GAA11 (ref)351 (ref)141 (ref)211 (ref)
AG+GG15N/A1351.0 (0.5–2.2)431.6 (0.4–7.9)920.7 (0.3–1.9)
MMP9
 C-1562TCC131 (ref)1241 (ref)461 (ref)781 (ref)
CT+TT30.6 (0.0–8.2)560.6 (0.3–1.2)110.5 (0.1–2.3)350.8 (0.4–1.7)
MMP12
 A-82GAA121 (ref)1311 (ref)401 (ref)911 (ref)
AG+GG40.3 (0.0–4.2)391.3 (0.6–2.6)171.1 (0.3–3.8)221.9 (0.7–5.2)
 A1082GAA131 (ref)1531 (ref)511 (ref)1021 (ref)
AG+GG30.6 (0.0–8.2)171.0 (0.4–2.8)6N/A112.3 (0.6–10.9)
  • Data are presented as crude OR (95% CI), unless otherwise stated. N/A: not applicable. Bold indicates significance. #: p = 0.03.